Daewoong Pharmaceutical Applies for Approval of New SGLT-2 Diabetes Drug 'EnbloPet' for Companion Dogs

Establishing a Foothold in the Global Animal Pharmaceutical Market

Daewoong Pharmaceutical announced on October 30 that it has applied to the Animal and Plant Quarantine Agency for product approval of 'EnbloPet' (ingredient: inavogliflozin), a diabetes treatment for companion dogs.

Daewoong Pharmaceutical

EnbloPet is a product developed by Daewoong Pharmaceutical by reformulating 'Enblo Tablet,' its SGLT-2 inhibitor diabetes medication for humans, into a dosage suitable for companion animals. Its efficacy and safety have been demonstrated through animal clinical trials.

'EnbloPet' is the world's first SGLT-2 inhibitor diabetes treatment for companion dogs. The results of Phase 2 clinical trials were announced in 2022, and Phase 3 trials began in 2023. This year, the clinical trials were successfully completed, and the scientific validity was established through the publication of research papers.

According to the results of the Phase 3 clinical trials, approximately 73.3% of companion dogs administered EnbloPet showed a significant decrease in fructosamine levels, a blood sugar indicator, and 60% also showed improvement in glycated hemoglobin (HbA1c) levels. In most cases, the amount of insulin used either stabilized or decreased, confirming the potential for more stable management of insulin administration.

Diabetes in companion dogs is similar to type 1 diabetes in humans and is difficult to manage without insulin administration. In particular, insufficient insulin can lead to ketoacidosis, while excessive insulin can cause hypoglycemic shock, making safety in the treatment process extremely important.

EnbloPet controls blood sugar by promoting the excretion of glucose through urine. Therefore, as an adjunctive therapy, it is significant in that it reduces insulin dependence, lowers risks, and enables more stable blood sugar management. It also addresses the limitations of existing treatments, where insulin requirements tend to increase over time after administration, and is being evaluated as a new treatment option that can slow disease progression.

The global market for animal diabetes treatments is projected to grow from $547 million (about 737.4 billion won) in 2024 to $1.1 billion (about 1.485 trillion won) by 2033.

Daewoong Pharmaceutical plans to fully enter the animal new drug business, starting with the development of EnbloPet. The company currently has a diverse pipeline, including an atopic dermatitis treatment for companion dogs, and is actively discussing technology exports with overseas animal pharmaceutical companies.

Park Sungsoo, CEO of Daewoong Pharmaceutical, stated, "In the field of diabetes treatment for companion dogs, where insulin monotherapy was previously the only option, 'EnbloPet' has presented a new alternative as an adjunctive prescription," adding, "We will continue to discover various indications utilizing the SGLT-2 inhibitor mechanism in the future."

This content was produced with the assistance of AI translation services.